Bessemer Group’s TG Therapeutics TGTX Stock Holding History

Bessemer Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.28M	Hold	132,555	–	–	0.01%	469
2026 Q1	$4.4M	Buy	132,555 +603	+0.5%	+$18K	0.01%	525
2025 Q4	$3.93M	Buy	131,952 +131,051	+14,545%	+$4.28M	0.01%	488
2025 Q3	$33K	Buy	901 +486	+117%	+$16K	﹤0.01%	1542
2025 Q2	$15K	Buy	415 +16	+4%	+$596	﹤0.01%	1669
2025 Q1	$16K	Buy	399 +127	+47%	+$4.27K	﹤0.01%	1612
2024 Q4	$8K	Buy	272 +135	+99%	+$3.87K	﹤0.01%	1874
2024 Q3	$3K	Buy	+137	New	+$2.99K	﹤0.01%	2133
2017 Q4	–	Sell	-1,403	Closed	-$17K	–	1818
2017 Q3	$17K	Hold	1,403	–	–	﹤0.01%	1525
2017 Q2	$14K	Buy	+1,403	New	+$15.7K	﹤0.01%	1541
2014 Q3	–	Sell	-2	Closed	–	–	1392
2014 Q2	$0	Hold	2	–	–	﹤0.01%	1469
2014 Q1	$0	Hold	2	–	–	﹤0.01%	1373
2013 Q4	$0	Buy	+2	New	+$8	﹤0.01%	1392

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Bessemer Group's TGTX Position: Q2 2026 in Review

Bessemer Group held its TG Therapeutics (TGTX) position steady in Q2 2026 at 132,555 shares worth $7.28M. The position accounts for 0.01% of the portfolio, ranked #469.

Bessemer Group first reported a position in TGTX in Q4 2013 and has held it in 13 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Bessemer Group held 132,555 shares of TG Therapeutics worth $7.28M as of Q2 2026.
Bessemer Group left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #469 holding.
Bessemer Group first reported a position in TG Therapeutics in Q4 2013 and has held it in 13 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.